PTC and Schaeffler Expand Strategic Relationship With Adoption of Windchill+ PLM
Leerink Partners Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Announces Target Price $52
Express News | PTC Therapeutics Inc : Leerink Partners Raises Target Price to $52 From $50
William Blair Maintains PTC Therapeutics(PTCT.US) With Buy Rating
PTC and Jazz Pharmaceuticals Among Latest Firms to Win EU Backing for Drugs
Positive Outlook for PTC Therapeutics: Buy Rating Affirmed Amid European and U.S. Approval Prospects for Sephience
Express News | RPT-EMA Says Chmp Recommended Granting Conditional Marketing Authorisation for Ziihera (Zanidatamab)
Express News | RPT-EMA Says Tepezza (Teprotumumab) Received Positive Opinion From Chmp for Treatment of Adults With Moderate to Severe Thyroid Eye Disease
Express News | RPT-EMA Says Chmp Recommends Conditional Marketing Authorisation for Duvyzat (Givinostat), as Treatment for Dmd in Patients From Age Six Who Can Walk
Express News | Corrected-EMA Says Chmp Will Re-Examine (Not 'requested Re-Examination of') Opinion Adopted for Marketing Authorisation Holder for Kisunla (Donanemab)
PTC Therapeutics Says Potential Phenylketonuria Drug Receives EU Panel's Positive Opinion
PTC Therapeutics Reports Update on Marketing Application for Sephience in Europe
Express News | PTC Therapeutics Inc - European Commission Expected to Ratify Sephience Authorization in Two Months
Express News | PTC Therapeutics Inc: European Launch Preparations Underway
Express News | PTC Therapeutics Receives Positive Chmp Opinion for Sephience™ (Sepiapterin) for the Treatment of Children and Adults Living With Phenylketonuria (Pku)
PTC Therapeutics CEO Makes Significant Stock Move
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $65
9 Health Care Stocks With Whale Alerts In Today's Session
RBC Capital Reiterates Outperform on PTC Therapeutics, Maintains $65 Price Target
PTC Therapeutics Insiders Sold US$2.9m Of Shares Suggesting Hesitancy